来自Rabdosia rubescens的奥里多宁:癌症治疗中的一个新兴潜力 - 一个全面的审查
Muhammad Asif Ali1, Noohela Khan2, Ahmad Ali1
1Department of Food Science and Human Nutrition UVAS Lahore Pakistan.
Food science & nutrition
|May 10, 2024
概括
植物化合物奥里多宁 (ORI) 通过表现出抗瘤特性,显示出对癌症治疗的潜力. 研究审查ORI的研究.
科学领域:
- 植物化学 植物化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 全球癌症发病率不断上升,需要新的治疗策略.
- 目前的癌症治疗有侵入性程序和副作用.
- 植物衍生化合物具有降低毒性和改善癌症管理的潜力.
研究的目的:
- 审查奥里多宁 (ORI) 的抗癌疗效.
- 探索ORI抗瘤活动背后的机制.
- 提供关于ORI在癌症治疗中的未来应用的见解.
主要方法:
- 关于奥里多宁 (ORI) 研究的综合文献综述.
- 从1976年到2022年的研究分析.
- 专注于ORI对小鼠和人类癌症模型的影响.
主要成果:
- 奥里多宁 (ORI) 具有显著的抗瘤和抗血管生成特性.
- ORI显示出抗炎和诱导亡的作用.
- 广泛的研究支持ORI的各种抗癌机制.
结论:
- 奥里多宁 (ORI) 是一种有前途的植物性化合物,用于癌症治疗.
- ORI的多方面的机制需要进一步调查.
- ORI有可能融入未来的癌症治疗方案.
更多相关视频
09:20Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts
Published on: June 26, 2018
8.4K
06:39Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
Published on: October 27, 2023
927
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Rous Sarcoma Virus (RSV) and Cancer
5.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.1K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
